Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,033.00 JPY | -0.73% |
|
+6.00% | +4.10% |
| 01:06pm | Takeda Pharmaceutical's Psoriasis Treatment Beats Competitor in Trial | MT |
| 12:01pm | Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial | RE |
| Market Cap | 7,951B 49.55B 43B 39.63B 37.14B 69.39B 4,744B 70.83B 473B 183B 2,287B 186B 182B | P/E Ratio 2026 |
46.4x | P/E Ratio 2027 * | 37.3x |
|---|---|---|---|---|---|
| Enterprise Value | 11,891B 74.1B 64.3B 59.27B 55.54B 104B 7,095B 106B 707B 274B 3,420B 278B 272B | EV / Sales 2026 |
1.14x | EV / Sales 2027 * | 2.56x |
| Free-Float |
99.25% | Yield 2026 |
3.53% | Yield 2027 * | 4.07% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -0.73% | ||
| 1 week | +6.00% | ||
| Current month | -1.66% | ||
| 1 month | -3.45% | ||
| 3 months | -11.96% | ||
| 6 months | +12.27% | ||
| Current year | +4.10% |
| 1 week | 4,896 |  | 5,086 |
| 1 month | 4,710 | | 5,362 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 59 | 31/03/2015 |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Weber
BRD | Director/Board Member | 59 | 31/05/2014 |
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
| Director/Board Member | 74 | 31/05/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-26 | Free | Executive/Senior Manager | 64,988 | 0.0041% | ||
| 04-26 | Free | Chief Technology Officer | 212,470 | 0.0134% | ||
| 04-26 | Free | Chief Financial Officer | 15,614 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73% | +6.00% | +15.30% | +10.93% | 49.92B | |
| +2.78% | +3.42% | +43.92% | +161.34% | 1,013B | |
| +0.44% | +5.11% | +54.46% | +49.98% | 574B | |
| +0.72% | +0.51% | +18.07% | +64.16% | 397B | |
| -0.37% | +4.97% | +21.24% | +15.95% | 324B | |
| +0.85% | +0.18% | +24.50% | +14.78% | 280B | |
| +2.10% | +4.92% | +25.30% | +33.80% | 273B | |
| +5.15% | +2.27% | +21.12% | +62.61% | 182B | |
| -0.19% | -0.46% | -45.32% | -48.35% | 194B | |
| +4.59% | -1.94% | +15.89% | +62.69% | 151B | |
| Average | +1.52% | +3.06% | +19.45% | +42.79% | 343.86B | |
| Weighted average by Cap. | +1.61% | +4.03% | +29.61% | +72.19% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 4,531B 28.24B 24.5B 22.59B 21.16B 39.54B 2,704B 40.37B 269B 104B 1,303B 106B 104B | 4,620B 28.79B 24.99B 23.03B 21.58B 40.32B 2,757B 41.16B 275B 106B 1,329B 108B 106B |
| Net income | 174B 1.09B 943M 870M 815M 1.52B 104B 1.55B 10.37B 4.02B 50.18B 4.08B 3.99B | 203B 1.27B 1.1B 1.01B 949M 1.77B 121B 1.81B 12.08B 4.68B 58.43B 4.75B 4.65B |
| Net Debt | 3,940B 24.55B 21.3B 19.64B 18.4B 34.38B 2,351B 35.1B 234B 90.69B 1,133B 92.16B 90.17B | 3,882B 24.19B 20.99B 19.35B 18.13B 33.87B 2,316B 34.58B 231B 89.36B 1,116B 90.8B 88.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/06/26 | 5,033.00 ¥ | -0.73% | 2,623,200 |
| 10/06/26 | 5,070.00 ¥ | +1.91% | 4,145,900 |
| 09/06/26 | 4,975.00 ¥ | -1.49% | 5,074,600 |
| 08/06/26 | 5,050.00 ¥ | +2.52% | 4,621,900 |
| 05/06/26 | 4,926.00 ¥ | +1.57% | 4,448,200 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
